Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
US Judge Dismisses Gautam Adani Criminal Charges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
 To Contact Brower Piven Before The Lead Plaintiff Deadline - EconoTimes)
STEVENSON, Md., Feb. 15, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) (“Ohr” or the “Company”) securities during the period between June 24, 2014 and January 4, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Ohr securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s lead product, Squalamine, would not produce vision improvements and was commercially not viable.
According to the complaint, following a January 5, 2018 report that topline data from its MAKO study did not meet its primary efficacy endpoint, the value of Ohr shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Ohr securities purchased on or after June 24, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]
